A carregar...
Impact of genetic alterations on mTOR-targeted cancer therapy
Rapamycin and its derivatives (rapalogs), a group of allosteric inhibitors of mammalian target of rapamycin (mTOR), have been actively tested in a variety of cancer clinical trials, and some have been approved by the Food and Drug Administration for the treatment of certain types of cancers. However...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Sun Yat-sen University Cancer Center
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3845552/ https://ncbi.nlm.nih.gov/pubmed/23489586 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5732/cjc.013.10005 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|